Cite
HARVARD Citation
Tse, C. et al. (2018). Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. Alimentary pharmacology & therapeutics. 48 (2), pp. 190-195. [Online].